Food and Behaviour Research

Donate Log In

A randomized controlled study of the efficacy of six-month supplementation with concentrated fish oil rich in omega-3 polyunsaturated fatty acids in first episode schizophrenia

Pawelczyk T, Grancow-Grabka M, Kotlicka-Antczak M, Trafalska E, Pawe┼éczyk A. (2016) J Psychiatr Res.  73 34-44. doi: 10.1016/j.jpsychires.2015.11.013. Epub 2015 Nov 25. 

Web URL: View this and related abstracts via PubMed here.

Abstract:

Short-term clinical trials of omega-3 polyunsaturated fatty acids (n-3 PUFA) as add-on therapy in patients with schizophrenia revealed mixed results. The majority of these studies used an 8- to 12-week intervention based on ethyl-eicosapentaenoic acid.

A randomized placebo-controlled trial was designed to compare the efficacy of 26-week intervention, composed of either 2.2 g/day of n-3 PUFA, or olive oil placebo, with regard to symptom severity in first-episode schizophrenia patients.

Seventy-one patients (aged 16-35) were enrolled in the study and randomly assigned to the study arms. The primary outcome measure of the clinical evaluation was schizophrenia symptom severity change measured by the Positive and Negative Syndrome Scale (PANSS).

Mixed models repeated measures analysis revealed significant differences between the study arms regarding total PANSS score change favouring n-3 PUFA (p = 0.016; effect size (ES) = 0.29). A fifty-percent improvement in symptom severity was achieved significantly more frequently in the n-3 PUFA group than in the placebo group (69.4 vs 40.0%; p = 0.017). N-3 PUFA intervention was also associated with an improvement in general psychopathology, measured by means of PANSS (p = 0.009; ES = 0.32), depressive symptoms (p = 0.006; ES = 0.34), the level of functioning (p = 0.01; ES = 0.31) and clinical global impression (p = 0.046; ES = 0.29).

The findings suggest that 6-month intervention with n-3 PUFA may be a valuable add-on therapy able to decrease the intensity of symptoms and improve the level of functioning in first-episode schizophrenia patients.

FAB RESEARCH COMMENT:

This placebo-controlled clinical trial found significant benefits for patients newly diagnosed with schizophrenia from the addition of dietary supplementation with long-chain omega-3 for 6 months to standard treatment.

In addition to reducing psychotic symptoms, the addition of omega-3 supplementation improved their general level of functioning.

These findings add to the existing evidence that an increased dietary omega-3 intake can be helpful in some patients with psychosis, as well as in the prevention of breakdown in individuals at high risk.  

See also: